December 12, 2005
MedImmune Nasal Flu Vaccine Beats Flu Shots in Trial
BOSTON -- MedImmune Inc. said on Monday that an easier-to-store version of its nasal spray flu vaccine significantly reduced the number of flu cases in an important clinical trial, sending its shares up as much as 8 percent.
The results come amid fears of a bird flu pandemic and a broader transformation of the market for vaccines, which has become the fastest-growing sector of the pharmaceuticals industry, according to analysts.
MedImmune said a late-stage, or Phase III, study of the vaccine, CAIV-T, showed that 3.9 percent of patients who took the vaccine came down with flu, compared with 8.6 percent of patients receiving conventional flu shots.
CAIV-T is a new version of the company's nasal spray vaccine FluMist, which is currently approved to prevent flu in healthy children and adolescents, 5 to 17 years of age, and healthy adults, 18 to 49 years of age.
FluMist, however, has to be kept frozen, an inconvenience that has contributed to disappointing sales of the vaccine, which was approved in 2003. CAIV-T can be kept refrigerated, making it easier to handle.
In addition, CAIV-T was tested in children ages 6 months through nearly five years. If approved, the company's ability to sell the vaccine to this population would substantially expand its market.
MedImmune plans to file for marketing approval for the vaccine in the second quarter of 2006 and will ask the U.S. Food and Drug Administration to give it a priority review. If approved, MedImmune expects to begin selling it as an alternative to the injectable flu vaccine beginning in the 2007 flu season.
A difference in side effects was seen mainly in children under two years of age who had not been previously vaccinated after the first dose. In these children significant wheezing occurred at a rate of 3.2 percent compared to 2 percent in those getting a conventional shot, the company said.
Shares of MedImmune rose $1.49 to $35.65 in mid-morning trading on Nasdaq after earlier touching $36.97.
(Additional reporting by Julie Steenhuysen in Chicago)